Innovex And StoneBridge Pharma, LLC Announce Parternship
Published: Apr 05, 2006
PARSIPPANY, N.J., April 5 /PRNewswire-FirstCall/ -- Innovex, the commercialization unit of Quintiles Transnational Corp., and StoneBridge Pharma LLC, a specialty pharmaceutical company, today announced an agreement that calls for the deployment of at least three waves of specialty sales representatives over the next 12 months. Innovex will provide teams of up to 75 specialty sales representatives across the country to support StoneBridge's sales and marketing efforts.
StoneBridge Pharma selected Innovex to support its sales efforts based on Innovex's proven track record for deploying Specialty Sales teams, as well as their analytical capabilities, which will assist StoneBridge with their strategic targeting efforts. StoneBridge Pharma products are focused in the gastroenterology, ophthalmology and women's health therapeutic areas.
"The selection of Innovex to support our sales efforts was based on the company's reputation for providing intelligent sales solutions. Innovex offered superior resources to back our sales professionals, and their use of analytics in strategically segmenting the market will greatly improve the effectiveness of our sales force," said Bob Sykora, President of StoneBridge.
"We are looking forward to demonstrating our sales expertise to StoneBridge Pharma," said Tony Yost, President of Innovex U.S. "We won this business because of our innovative use of analytics to improve sales force effectiveness and our ability to rapidly recruit and deploy experienced sales professionals. We go beyond simply providing sales representatives as our people are empowered by information and technologies that enhance sales planning, tracking and results."
Innovex, the commercialization division of Quintiles Transnational Corp., is a leading commercial solutions provider that offers sales and marketing services designed to accelerate the success of pharmaceutical, biotechnology and medical device products. Since 1996, Innovex has built more than 150 sales and Health Management Services teams, and hired more than 16,000 sales representatives and 500 clinicians to help launch more than 160 products for leading pharmaceutical companies in the United States. For more information, visit www.innovex.com.
Quintiles is the global leader in pharmaceutical services. We improve healthcare worldwide by providing quality professional expertise, market intelligence and innovative partnering solutions to the pharmaceutical, biotechnology and healthcare industries. Quintiles has 16,000 specialized employees and offices in 50 countries. For more information visit the company's Web site at www.quintiles.com.
This press release contains "forward-looking statements" regarding Quintiles that involve risks and uncertainties that could cause actual results to differ materially, including, without limitation, the risk that the market for our products and services will not grow as we expect, our ability to efficiently distribute backlog among therapeutic business units and match demand to resources, actual operating performance, the ability to maintain large client contracts or to enter new contracts, changes in trends in the pharmaceutical industry and the ability to operate successfully in new lines of business. Additional factors that could cause actual results to differ materially are discussed in Quintiles' recent filings with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10-K, its Form 8-Ks, and its other periodic reports, including Form 10-Qs.
StoneBridge Pharma, a Georgia-based LLC, is a specialty pharmaceutical company focused on solutions to address unmet needs that are clinically useful and financially advantageous to the patient, physician and StoneBridge in the areas of gastroenterology, ophthalmology and women's health. Since its creation in 2005, StoneBridge has cultivated a culture that values entrepreneurial zeal, innovation, market knowledge and service excellence in order to identify the most critical healthcare issues for its market segments, develop solutions to those issues and measurably improve quality of care.
StoneBridge Pharma has a simple -- yet powerful -- business strategy: 1. Seek partnerships with companies that have successful and proven products. 2. Use the knowledge and expertise of a management team with more than a century of collective experience in the pharmaceutical industry. 3. Maximize the performance of a specialized and highly targeted sales and marketing team. 4. Use a variety of approaches to revitalize and re-market products such as: a. Marketing new drug delivery methods or formulations b. Initiate special sales and marketing programs through the focused sales team
StoneBridge Pharma is a leader in alliance management with its focused approach of maximizing value from product initiation through product maturity to lifecycle optimization, following patent expiration. For more information, visit the company's website at www.stonebridgepharma.com.Quintiles Transnational Corp.
CONTACT: Mari Mansfield, media relations of Quintiles Transnational Corp.,+1-919-998-2639, or email@example.com; or Robert C. Sykora, RPh,President of StoneBridge Pharma, +1-877-528-6593, firstname.lastname@example.org